Bristol Biotech spin out, Ziylo, acquired by Novo Nordisk

University of Bristol spinout Ziylo has been acquired by Novo Nordisk in a deal worth up to $800 million. Ziylo has been pioneering the use of its platform technology - synthetic glucose binding molecules - for therapeutic and diagnostic applications.  The acquisition gives Novo Nordisk full rights to Ziylo's platform to develop glucose responsive insulins. This technology could be key in developing the next generation of insulin leading to safer and more effective therapy. Ziylo was co-founded by Dr Harry Destecroix,…